Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Non Operating Income (2016 - 2025)

Catalyst Pharmaceuticals (CPRX) has disclosed Non Operating Income for 12 consecutive years, with $10.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non Operating Income fell 11.32% year-over-year to $10.1 million, compared with a TTM value of $25.7 million through Dec 2025, up 21.75%, and an annual FY2025 reading of $25.7 million, up 21.75% over the prior year.
  • Non Operating Income was $10.1 million for Q4 2025 at Catalyst Pharmaceuticals, up from $4.8 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $11.3 million in Q4 2024 and bottomed at -$833000.0 in Q3 2023.
  • Average Non Operating Income over 5 years is $2.9 million, with a median of $1.8 million recorded in 2023.
  • Peak annual rise in Non Operating Income hit 3008.45% in 2022, while the deepest fall reached 622.58% in 2022.
  • Year by year, Non Operating Income stood at $71000.0 in 2021, then skyrocketed by 3008.45% to $2.2 million in 2022, then soared by 127.23% to $5.0 million in 2023, then soared by 126.08% to $11.3 million in 2024, then fell by 11.32% to $10.1 million in 2025.
  • Business Quant data shows Non Operating Income for CPRX at $10.1 million in Q4 2025, $4.8 million in Q3 2025, and $3.0 million in Q2 2025.